FindTrial
Sign In

Irinotecan liposomes

DRUG2 trials

Sponsors

Shanghai Runshi Pharmaceutical Technology Co., Ltd, Harbin Medical University

Conditions

Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the PastExpressing Human Epidermal Growth Factor Receptor-2 (HER-2)Intrahepatic Cholangiocarcinoma (Icc)Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Phase 1

A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Not yet recruitingNCT06577376
Shanghai Runshi Pharmaceutical Technology Co., LtdDisease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past, Expressing Human Epidermal Growth Factor Receptor-2 (HER-2), Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
Start: 2024-08-26End: 2027-08-26Target: 252Updated: 2024-09-05

Phase 2

Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
Not yet recruitingNCT06648525
Harbin Medical UniversityIntrahepatic Cholangiocarcinoma (Icc)
Start: 2024-10-31End: 2028-04-30Target: 68Updated: 2024-10-18